Drugs / PELTOPEPIMUT-S

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00257738 Nov 2005 → Oct 2012 head and neck squamous cell carcinoma University of Maryland, Baltimore Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02128126 Sep 2013 → Aug 2018 cervical cancer ISA Pharmaceuticals Completed No outcome recorded
Phase 25 trials
Phase 2 NCT04398524 Jul 2021 → Jun 2024 oropharynx squamous cell carcinoma ISA Pharmaceuticals Unknown No outcome recorded
Phase 2 NCT04646005 Jun 2021 → May 2023 cervical cancer Regeneron Pharmaceuticals Completed No outcome recorded
Phase 2 NCT04369937 Jul 2020 → Mar 2025 head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma Dan Zandberg Completed No outcome recorded
Phase 2 NCT03669718 Nov 2018 → Sep 2024 human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma ISA Pharmaceuticals Unknown No outcome recorded
Phase 2 NCT03258008 Apr 2018 → Nov 2021 cancer of unknown primary site, oropharynx squamous cell carcinoma M.D. Anderson Cancer Center Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as PELTOPEPIMUT-S ChEMBL registry synonym — accepted as the source's own label CHEMBL5095477
Known as HPV-16 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257738
Known as ISA101b ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669718
5

NCT04398524

NCT02128126

NCT04369937

NCT03258008

NCT04646005

Modality Vaccine “MAGE-A3/HPV 16 VaccineNCT00257738
Route Subcutaneous “Administered Subcutaneously” NCT00257738